Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 6/20 | 0.79 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | OXTR | P30559 | 1/20 | 0.79 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.79 |
| ▸ | CD81 | P60033 | 1/20 | 0.79 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | RELA | Q04206 | 4/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.62 |
| ▸ | USP7 | Q93009 | 3/20 | 0.62 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.62 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.62 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.62 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.62 |
| ▸ | PTPRC | P08575 | 2/20 | 0.62 |
| ▸ | PTPRF | P10586 | 2/20 | 0.62 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quillaic Acid SCHEMBL18712201 | 1.00 | F3 (0.79) | F3SIRT5CYP3A4MAPK1OXTR | |
| Quillaic Acid SCHEMBL18704373 | 1.00 | F3 (0.79) | F3SIRT5CYP3A4MAPK1OXTR | |
| Quillaic Acid SCHEMBL26373052 | 1.00 | F3 (0.79) | F3SIRT5CYP3A4MAPK1OXTR | |
| Quillaic Acid SCHEMBL18712199 | 1.00 | F3 (0.79) | F3SIRT5CYP3A4MAPK1OXTR | |
| Quillaic Acid SCHEMBL867116 | 1.00 | F3 (0.79) | F3SIRT5CYP3A4MAPK1OXTR | |
| Quillaic Acid SCHEMBL26759724 | 1.00 | F3 (0.79) | F3SIRT5CYP3A4MAPK1OXTR | |
| Quillaic Acid SCHEMBL7770255 | 1.00 | F3 (0.79) | F3SIRT5CYP3A4MAPK1OXTR | |
| Quillaic Acid SCHEMBL18712200 | 1.00 | F3 (0.79) | F3SIRT5CYP3A4MAPK1OXTR | |
| SCHEMBL18712772 | 0.91 | F3 (0.66) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL741321 | 0.88 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 898 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087679-A1 | TREATMENT FOR DISORDERS OF THE KIDNEY OR SPLEEN | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087678-A1 | TREATMENT FOR RENAL DISORDERS | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731261-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | claimed |
| EP-4731257-A1 | CONJUGATES OF SAPONIN AND ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | claimed |
| EP-4719478-A1 | IMPROVED TREATMENT REGIMENS FOR THERAPEUTIC EFFECTOR COMPONENTS THAT ACT VIA AN INTRACELLULAR MOLECULAR TARGET | Sapreme Technologies B.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-3915587-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2026-03-25 | — | — | EP | claimed |
| US-20260077055-A1 | COMPOSITIONS OF POLYPLEXES AND SAPONINS | SAPREME TECH BV (NL) | 2026-03-19 | — | — | US | claimed |
| US-20260049342-A1 | METHODS AND COMPOSITIONS RELATING TO THE SYNTHESIS OF THE QS-7 MOLECULE | PLANT BIOSCIENCE LTD (GB) | 2026-02-19 | — | — | US | claimed |
| EP-0996451-B1 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | GALENICA PHARMACEUTICALS INC (US) | 2005-01-05 | — | — | EP | claimed |
| EP-1476018-A1 | IMMUNOSTIMULANT COMPOSITIONS COMPRISING AMINOALKYL GLUCOSAMINIDE PHOSPHATES AND SAPONINS | CORIXA CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| US-20030190333-A1 | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins | CORIXA CORPORATION (US) | 2003-10-09 | — | — | US | claimed |
| WO-2003069997-A1 | IMMUNOSTIMULANT COMPOSITIONS COMPRISING AMINOALKYL GLUCOSAMINIDE PHOSPHATES AND SAPONINS | CORIXA CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0996451-A4 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | GALENICA PHARMACEUTICALS INC (US) | 2001-04-18 | — | — | EP | claimed |
| EP-0996451-A1 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | Galenica Pharmaceuticals, Inc. (US) | 2000-05-03 | — | — | EP | claimed |
| US-5977081-A | PLANT EXTRACT; ADJUST IMMUNOLOGY RESPONSE | GALENICA PHARMACEUTICALS, INC. (US) | 1999-11-02 | — | — | US | claimed |
| WO-1998052573-A1 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | GALENICA PHARMACEUTICALS, INC. (US) | 1998-11-26 | — | — | WO | claimed |
| CN-86103736-A | The preparation method that is used for the treatment of the bacteria composition of amimal gastroenteropathy | — | 1987-05-20 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190333-A1 | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins | DDOST, TLR6, ENPP2 | F3 4056/4885SIRT5 4378/4885CYP3A4 4187/4885 |
| US-20260049342-A1 | METHODS AND COMPOSITIONS RELATING TO THE SYNTHESIS OF THE QS-7 MOLECULE | QPCT, QTRT1, ACAT2 | F3 2408/4885SIRT5 1235/4885CYP3A4 1891/4885 |
| US-20260077055-A1 | COMPOSITIONS OF POLYPLEXES AND SAPONINS | GAA, EEA1, RNASE1 | F3 3737/4885SIRT5 4416/4885CYP3A4 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.